Back to News
Market Impact: 0.25
Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Ligand Pharmaceuticals acquired royalty and milestone-payment rights linked to Santen Pharmaceutical's Ryjunea, the first approved drug treatment in Europe and the UK designed to slow myopia progression in children. The transaction expands Ligand's portfolio of royalty-based healthcare assets, though no purchase price or expected financial contribution was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
LGND0.65
More News
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Paramount will need to release way more movies to make this merger work
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Australia’s IDP shares drop after rejecting $494 mln Blackstone offer
- Lennar shares pop as Berkshire builds almost a 10% stake in beleaguered homebuilder
- Royal Caribbean nears $3 billion deal to take 50% equity stake in Sandals
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Exactly Does Post-Training in LLMs and Finance-Focused AI Actually Mean for Asset Managers?
- What Is a Financial Ontology?